Rapamycin is a widely used drug for cancer and transplant patients, and there are hints that it might even help us put off old age and live longer. But, it also comes with a downside: rapamycin leads to diabetes in as many as 15 percent of the people who take it. Researchers at Dana-Farber Cancer Institute have figured out that the drug turns the insulin signal off in muscle, preventing muscle cells from taking blood sugar in. The team found that the key is a single transcription factor in...
↧
